Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. (2022)

First Author: Moss P
Attributed to:  Phase 1 COVID-19 Immunity - National Core Study funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.vaccine.2022.05.067

PubMed Identifier: 35718592

Publication URI: http://europepmc.org/abstract/MED/35718592

Type: Journal Article/Review

Volume: 40

Parent Publication: Vaccine

Issue: 32

ISSN: 0264-410X